Key facts
- This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2021, 21:25.
David Arkowitz - 01 Jun 2021 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MCRB
- Reported as of
- 01 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2021, 21:25:15 UTC
- Prior SEC filing
- 12 May 2021
- Next SEC filing
- 04 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s//Thomas J. DesRosier, Attorney-in-Fact for David Arkowitz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 01 Jun 2021.
Change
- Previous filing in this sequence was filed on 12 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +270,000
- Change %
- Price
- $0.000000
- Shares after
- 270,000
- Date
- 01 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 270,000
- Exercise price
- $20.19
- Footnotes
- F1
MCRB
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- Price
- $0.000000
- Shares after
- 5,000
- Date
- 01 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option will vest and become exercisable as to 25% of the shares on June 1, 2022. The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F3
100% of the restricted stock units will vest and settle on June 15, 2022. The restricted stock units have no expiration date.